Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 18, 2021

Biogen begins dosing in Phase III trial of lupus erythematosus drug

The Phase III trial will assess the decrease in disease activity at week 52 as its primary objective.

Biogen has started dosing participants in the Phase III TOPAZ-1 clinical trial of BIIB059 for the treatment of active systemic lupus erythematosus (SLE).

BIIB059 is a humanised IgG1 monoclonal antibody (mAb) that acts on blood dendritic cell antigen 2 (BDCA2). It is being developed to potentially treat SLE and cutaneous lupus erythematosus (CLE).

The multi-centre, randomised double-blind, placebo-controlled TOPAZ-1 trial will test the safety and clinical efficacy of the drug candidate in 540 active SLE patients, when compared to placebo, at roughly 135 centres globally.

Apart from their ongoing lupus therapy, participants in the 52-week trial will be administered subcutaneous BIIB059 at one of two doses or placebo every four weeks, followed by another dose at week 2.

The trial’s primary objective is a decrease in disease activity determined as the proportion of subjects experiencing an SLE Responder Index-4 (SRI-4) response at week 52.

Key secondary endpoints include other efficacy parameters, such as SRI-4 response at week 24, oral corticosteroid use, organ-specific disease activity (joint and/or skin) and flare rates.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

TOPAZ-1 is based on the data from the Phase II LILAC trial, where BIIB059 met its primary endpoint with a statistically significant decrease of disease activity in SLE patients.

Biogen Multiple Sclerosis and Immunology Development unit head Nathalie Franchimont said: “We have set enrolment targets that reflect the prevalence of SLE in African-American and Hispanic/Latinx communities with the aim to achieve appropriate representation in the TOPAZ-1 study.”

This development comes a day after the company reported that its Alzheimer’s disease treatment candidate, gosuranemab (BIIB092), failed to meet the primary efficacy endpoint in the Phase II TANGO clinical trial.

Based on TANGO data, Biogen decided to discontinue the clinical development of gosuranemab, which targets the N-terminus of tau.

Last week, Biogen and its partner Eisai received accelerated approval from the US Food and Drug Administration for their human monoclonal antibody Aduhelm (aducanumab-avwa) to treat Alzheimer’s.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU